Kraig Biocraft Laboratories is Happy to Announce its New Director of Molecular Biology as it Accelerates Advanced Fibers Development
Kraig Biocraft Laboratories (OTCQB: KBLB), a leader in spider silk-based super materials, has appointed Dr. Xiaoli Zhang as Director of Molecular Biology. Dr. Zhang, recognized for her groundbreaking work in spider silk and transgenic silkworms research, has already achieved significant breakthroughs in developing new spider silk-based fibers with enhanced capabilities.
The appointment strengthens the company's R&D capabilities as it accelerates the transition from laboratory development to large-scale commercialization of these revolutionary materials. Dr. Zhang's expertise in genetic engineering and bioengineering, backed by peer-reviewed publications, has been important in optimizing the company's genetic engineering of silkworms for spider silk production.
Kraig Biocraft Laboratories (OTCQB: KBLB), leader nei super materiali basati sulla seta di ragno, ha nominato Dr. Xiaoli Zhang come Direttore della Biologia Molecolare. La Dr.ssa Zhang, riconosciuta per il suo lavoro innovativo nella ricerca sulla seta di ragno e sui bachi da seta transgenici, ha già ottenuto importanti risultati nello sviluppo di nuove fibre di seta di ragno con capacità potenziate.
Questa nomina rafforza le capacità di ricerca e sviluppo dell'azienda mentre accelera la transizione dallo sviluppo in laboratorio alla commercializzazione su larga scala di questi materiali rivoluzionari. L'expertise della Dr.ssa Zhang in ingegneria genetica e bioingegneria, supportata da pubblicazioni sottoposte a revisione paritaria, è stata fondamentale nell'ottimizzazione dell'ingegneria genetica dei bachi da seta per la produzione di seta di ragno.
Kraig Biocraft Laboratories (OTCQB: KBLB), líder en materiales super basados en seda de araña, ha nombrado a Dr. Xiaoli Zhang como Directora de Biología Molecular. La Dra. Zhang, reconocida por su trabajo innovador en la investigación de seda de araña y gusanos de seda transgénicos, ya ha logrado avances significativos en el desarrollo de nuevas fibras basadas en seda de araña con capacidades mejoradas.
Esta designación fortalece las capacidades de I+D de la empresa mientras acelera la transición del desarrollo en laboratorio a la comercialización a gran escala de estos materiales revolucionarios. La experiencia de la Dra. Zhang en ingeniería genética y bioingeniería, respaldada por publicaciones revisadas por pares, ha sido importante para optimizar la ingeniería genética de los gusanos de seda para la producción de seda de araña.
크레이그 바이오크래프트 연구소 (OTCQB: KBLB), 거미 실크 기반 초고강도 소재의 선두주자로, 샤오리 장 박사를 분자 생물학 이사로 임명했습니다. 장 박사는 거미 실크와 트랜스제닉 누에 연구에서의 획기적인 작업으로 인정받아, 향상된 기능을 가진 새로운 거미 실크 기반 섬유 개발에서 이미 중요한 돌파구를 이뤘습니다.
이번 임명은 실험실 개발에서 대규모 상업화로의 전환을 가속화하면서 회사의 연구개발 능력을 강화합니다. 장 박사의 유전공학 및 생명공학 전문성은 동료 검토된 출판물에 의해 뒷받침되며, 거미 실크 생산을 위한 누에의 유전공학 최적화에 중요한 역할을 해왔습니다.
Kraig Biocraft Laboratories (OTCQB: KBLB), un leader dans les supermatériaux à base de soie d'araignée, a nommé Dr. Xiaoli Zhang au poste de Directrice de la Biologie Moléculaire. La Dr Zhang, reconnue pour ses travaux novateurs sur la soie d'araignée et les vers à soie transgéniques, a déjà réalisé des avancées significatives dans le développement de nouvelles fibres à base de soie d'araignée avec des capacités améliorées.
Cette nomination renforce les capacités de recherche et développement de l'entreprise tout en accélérant la transition du développement en laboratoire à la commercialisation à grande échelle de ces matériaux révolutionnaires. L'expertise de la Dr Zhang en ingénierie génétique et en bio-ingénierie, soutenue par des publications évaluées par des pairs, a été essentielle pour optimiser l'ingénierie génétique des vers à soie pour la production de soie d'araignée.
Kraig Biocraft Laboratories (OTCQB: KBLB), ein führendes Unternehmen im Bereich der auf Spinnenseide basierenden Supermaterialien, hat Dr. Xiaoli Zhang zur Direktorin der Molekularbiologie ernannt. Dr. Zhang, die für ihre bahnbrechenden Arbeiten zur Spinnenseide und transgenen Seidenspinnern anerkannt ist, hat bereits bedeutende Durchbrüche bei der Entwicklung neuer Spinnenseide-basierten Fasern mit verbesserten Eigenschaften erzielt.
Die Ernennung stärkt die F&E-Fähigkeiten des Unternehmens, während sie den Übergang von der Laborentwicklung zur großflächigen Kommerzialisierung dieser revolutionären Materialien beschleunigt. Dr. Zhangs Fachwissen in der Gentechnik und Bioengineering, unterstützt durch peer-reviewed Publikationen, war entscheidend für die Optimierung der genetischen Manipulation von Seidenspinnern zur Produktion von Spinnenseide.
- Appointment of highly qualified Director with proven expertise in spider silk research
- Recent breakthrough developments in new spider silk-based fibers
- Acceleration toward large-scale commercialization
- Enhanced R&D capabilities through new leadership
- None.
ANN ARBOR, Mich., April 07, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk-based super materials, is pleased to announce the appointment of Dr. Xiaoli Zhang as Director of Molecular Biology.
Dr. Zhang is a proven research and development leader in the field of molecular biology and bioengineering, with numerous groundbreaking accomplishments in spider silk and transgenic silkworms, including publication and citations in peer-reviewed scientific journals. Her research has been pivotal in optimizing the Company’s genetic engineering of silkworms to produce high-performance spider silk.
In the very short time she has worked directly with Kraig Labs, she has rapidly achieved significant breakthroughs in the development of brand-new spider silk-based fibers that target capabilities beyond the currently available materials. The Company is now accelerating the transition of these new developments out of the laboratory with a focus on large-scale commercialization of these revolutionary materials.
"We are thrilled to recognize Dr. Zhang's invaluable contributions to the development of advanced biomaterials, including spider silk, by appointing her to the pivotal position of Director of our Molecular Biology laboratory and R&D center," said Kim Thompson, CEO and Founder of Kraig Biocraft Laboratories. "Her expertise and leadership have been essential in driving the development of our next-generation spider silk technology and in our adoption of new genetic engineering technologies. As we continue to push the boundaries of what's possible in material science, Dr. Zhang's vision and dedication will be instrumental in shaping the future of biomaterials."
Throughout her career, Dr. Zhang has demonstrated a commitment to innovation in genetic engineering, making her a recognized leader in the field. Her work at Kraig Labs has accelerated the Company's ability to create new advanced biomaterials.
"I am honored to take on this new role at Kraig Biocraft Laboratories," said Dr. Zhang. "The advancements we've made in spider silk production are just the beginning of what's possible. I look forward to continuing our groundbreaking work and bringing this incredible material to market at scale."
Dr. Zhang's appointment underscores the Company’s commitment to scientific excellence and innovation in biomaterials. As Kraig Labs advances its commercial rollout of spider silk-based textiles, her leadership will be critical in ensuring continued success in the field of bioengineered materials.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3c3e02ec-249f-4f8c-b4ba-adf80a28a684
FAQ
What breakthrough has Dr. Zhang achieved at Kraig Biocraft Laboratories (KBLB)?
How will Dr. Zhang's appointment impact KBLB's commercialization plans?
What is KBLB's current focus in spider silk development?
What are Dr. Zhang's credentials for leading KBLB's molecular biology division?
